Statistics for Targeting LINC00152 activates cAMP/Ca²⁺/ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancer
Total visits
| views | |
|---|---|
| Targeting LINC00152 activates cAMP/Ca²⁺/ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancer | 5 |
Total visits per month
| views | |
|---|---|
| November 2024 | 0 |
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 1 |
| March 2025 | 4 |
| April 2025 | 0 |
| May 2025 | 0 |
File Visits
| views | |
|---|---|
| Targeting_LINC00152_activates_cAMP_Ca2_ferroptosis_axis_and_overcomes_tamoxifen_resistance_in_ER_plus_breast_cancer.pdf | 25 |
Top country views
| views | |
|---|---|
| Turkey | 2 |
| United States | 2 |
| Netherlands | 1 |
Top city views
| views | |
|---|---|
| Bellerose | 1 |
| Columbia | 1 |
| Sincan | 1 |